DUBLIN–(BUSINESS WIRE)–The “Global Polycystic Kidney Disease Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
Global Polycystic Kidney Disease Drugs Market: About this market
The special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.
Polycystic kidney disease is a genetic disorder in which clusters of cysts develop primarily within the kidneys, causing kidneys to enlarge and lose function over time. This polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). Our analysis also considers the sales of polycystic kidney disease drugs in North America, Europe, Asia, and ROW. In 2018, the ARPKD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of the disease will play a significant role in the ARPKD segment to maintain its market position. Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs. However, the lack of approved drugs, availability of substitute treatment options, and stringent regulations may hamper the growth of the polycystic kidney disease drugs industry over the forecast period.
Global polycystic kidney disease drugs market: Overview
Special regulatory designations
The growing focus on developing and evaluating drugs that effectively cure and diagnose rare diseases is encouraging organizations such as the US FDA and EMA to provide special regulatory designations to underlying companies. This provides companies with benefits such as tax credits for clinical trials and protocol assistance. These designations help vendors to easily launch drugs, which will help them in generating revenues.
Favorable reimbursement policies
The high cost of off-label drugs and the approved novel drug for the treatment of polycystic kidney disease makes it challenging for patients to afford it. Hence, government and non-government organizations are introducing reimbursement policies to help patients in availing the treatment. These policies are further encouraging vendors to increase investments in R&D. Thus, the presence of favorable reimbursement policies will fuel the growth of the market.
With the presence of several major players, the global polycystic kidney disease drugs market is moderately fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs providers.
Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- ADPKD – Market size and forecast 2018-2023
- ARPKD – Market size and forecast 2018-2023
- Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Increasing research funding
- Favorable reimbursement policies
- Growing awareness about kidney diseases
PART 13: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Otsuka Holdings Co. Ltd.
- Reata Pharmaceuticals Inc.
PART 15: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 16: EXPLORE
For more information about this report visit https://www.researchandmarkets.com/r/eir4qt
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs